Back to Freestone Grove Partners LP Freestone Grove Partners LP

PRAXPRAX

4 quarters

Position history for Freestone Grove Partners LPFreestone Grove Partners LP's holdings in Praxis Precision Medicines, Inc.

No. Freestone Grove Partners exited its PRAX (Praxis Precision Medicines) position in Q4 2025. Its Q3 2025 13F listed 8,269 shares worth $438,257. Freestone Grove Partners already held PRAX in its Q4 2024 13F, the earliest on record, and held it in 2 quarterly 13F filings.

Final Value

$0

Final Shares

0

Total Value Change

-$237,037

Total Shares Change

-3,080

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2025-Q4
Latest
Exited
0
-100.0%
$00.0%$294.74
0
2025-Q3
New
8,269
—
$438,2570.0%$52.38
33
2025-Q1
Exited
0
-100.0%
$00.0%$38.66
0
2024-Q4
First report
3,080
—
$237,0370.0%$76.26
0

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used